Rational biomarker development for the early and minimally invasive monitoring of AML

Recurrent disease remains the principal cause for treatment failure in acute myeloid leukemia (AML) across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhamed, Sherif, Butler, John T., Jung, Seul, Chen, Ding-Wen, Jenkins, Gaye, Gao, Lina, Lim, Jeong Y., Klco, Jeffery M., Horton, Terzah M., Kurre, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579272/
https://www.ncbi.nlm.nih.gov/pubmed/34587228
http://dx.doi.org/10.1182/bloodadvances.2021004621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579272/
https://www.ncbi.nlm.nih.gov/pubmed/34587228
http://dx.doi.org/10.1182/bloodadvances.2021004621

Ejemplares similares